CD4 + helper T cells acquire effector phenotypes that promote specialized inflammatory responses. We show that the ETSfamily transcription factor PU.1 was required for the development of an interleukin 9 (IL-9)-secreting subset of helper T cells. Decreasing PU.1 expression either by conditional deletion in mouse T cells or the use of small interfering RNA in human T cells impaired IL-9 production, whereas ectopic PU.1 expression promoted IL-9 production. Mice with PU.1-deficient T cells developed normal T helper type 2 (T H 2) responses in vivo but showed attenuated allergic pulmonary inflammation that corresponded to lower expression of Il9 and chemokines in peripheral T cells and in lungs than that of wild-type mice. Together our data suggest a critical role for PU.1 in generating the IL-9-producing (T H 9) phenotype and in the development of allergic inflammation.
Helper T cells promote the development of specific types of inflammation after differentiating into various effector subsets. The cytokine microenvironment present when a naive helper T cell is activated determines the developmental pathway. Interleukin 4 (IL-4; A001262) promotes the differentiation of T helper type 2 (T H 2) cells and allergic inflammation. IL-12 promotes T H 1 differentiation, whereas inflammatory cytokines, including transforming growth factor-β (TGF-β1), IL-6, IL-1 and IL-23, stimulate the development of IL-17-producing T helper cells (T H 17 cells); both of these cell types contribute to autoimmune inflammation [1] [2] [3] . Helper T cell differentiation and the establishment of effector phenotypes are governed by a network of transcription factors that regulate the expression of cytokines and other effector genes. For example, T H 2 development requires IL-4-induced activation of the transcription factor STAT6, followed by subsequent induction of the transcription factor GATA-3, a T H 2 lineage-promoting factor. The ability of T H 2 cells to respond to subsequent T cell antigen receptor stimulation with rapid induction of T H 2-specific cytokines further requires members of the transcription factor NFAT and Jun families and the transcription factors c-Maf and IRF4, probably among other factors, for transactivation of loci encoding cytokines [4] [5] [6] .
The transcription factor PU.1 (A001950) also contributes to the T H 2 phenotype by promoting heterogeneity of T H 2 cytokine secretion 7, 8 . PU.1 is expressed specifically in subpopulations of T H 2 cells with low IL-4 expression. Ectopic expression of PU.1 results in lower production of most T H 2 cytokines, whereas short hairpin RNA that decreases PU.1 expression or PU.1 deficiency results in greater overall cytokine production specifically in populations of cells that secrete two or more cytokines 7, 8 . PU.1 functions at least in part by limiting the ability of GATA-3 and IRF4 to interact with target loci encoding cytokines [7] [8] [9] .
IL-9 (A001559) has long been thought to be a T H 2 cytokine, as it promotes allergic inflammation and is associated with various T H 2 responses 10 . Transgenic expression of Il9 results in allergic inflammation [11] [12] [13] . IL-9 promotes mucus production from lung epithelial cells and pulmonary mastocytosis [14] [15] [16] [17] . Although allergic inflammation can develop in Il9 −/− mice in a standard sensitizationchallenge model, blockade of IL-9 in a similar model results in less allergic inflammation 18, 19 . IL-9 expression is higher in lungs of asthmatic patients 20, 21 , and blocking antibodies are being developed as a therapy for atopic disease 22 . IL-9 may contribute to extracellular parasite immunity 23, 24 . IL-9 has also been shown to promote the development of T H 17 cells while increasing the activity of regulatory T cells (T reg cells) 25, 26 , which suggests that IL-9 biology may be more complex.
In addition to the established helper T cell subsets, reports have described an IL-9-secreting population of T cells 27 . T H 2 cells and T reg cells can produce IL-9 (ref. 28) , and culture with TGF-β1 may result in more IL-9 production by many cell types 26 . A helper T cell subset called 'T H 9 cells' is derived in culture with a combination of TGF-β1 and IL- 4 (refs. 24,29) . These cells are related to T H 2 cells in that they require STAT6 and GATA-3 for development, but they have lower expression 5 2 8 VOLUME 11 NUMBER 6 JUNE 2010 nature immunology A r t i c l e s of T H 2 cytokines 24, 29 . Transcription factors that specifically control the IL-9-secreting T cell phenotype have not yet been identified.
In this report we identify PU.1 as a regulator of IL-9 production in T cells. PU.1-deficient T cells had less IL-9 production, and ectopic expression of PU.1 resulted in more IL-9 production by T H 2 and T H 9 cell cultures. Diminishing PU.1 expression in human IL-9-secreting T cell cultures also resulted in less IL-9 production. In mice that lacked PU.1 only in T cells, allergic airway inflammation was attenuated, and this observation correlated with less production of IL-9 and PU.1-induced production of chemokines in the lung. These results suggest that PU.1 is a critical regulator of the IL-9-secreting T cell phenotype and is important for the development of allergic inflammation.
RESULTS

PU.1 promotes the development of IL-9-secreting T cells
Initial descriptions of the IL-9-secreting helper T cells (called 'T H 9 cells' here) did not identify a transcription factor that distinguished these cells as a distinct lineage 24, 29 . PU.1 limits T H 2 cytokine production in T cells 7, 8 , which suggests that it could be involved in the T H 9 phenotype. To test that hypothesis, we differentiated naive T cells from wild-type mice and PU.1-deficient mice (Sfpi1 fl/fl Lck-Cre mice, in which loxP-flanked alleles of the gene encoding PU.1 are deleted by Cre recombinase driven by the promoter of the gene encoding the kinase Lck, which results in deletion mainly in T cells) under T H 9 conditions (TGF-β1 plus IL-4). We observed that IL-9 secretion, mRNA expression and IL-9 intracellular staining were lower in T H 9 cultures that lacked PU.1 expression (Fig. 1a-c) .
PU.1 expression was low in T H 1 cells, and in T H 2 populations PU.1 was expressed in IL-4 lo cells but not IL-4 hi cells 8 . To compare the expression of PU.1 in additional helper T cell subsets, we generated T H 1, T H 2, T H 17 and T H 9 cells and analyzed expression of RNA encoding PU.1. We observed that T H 1 and T H 17 cells had the lowest expression of Sfpi1 mRNA, T H 2 cells had three-to fivefold more abundant Sfpi1 mRNA expression, and T H 9 cells expressed approximately threefold more Sfpi1 than did T H 2 cells (Fig. 1d) . Inducible T reg (iT reg ) cultures expressed even more Sfpi1 mRNA than did T H 9 cell cultures ( Supplementary Fig. 1a) , which suggested that Sfpi1 might be a TGF-β-induced gene. Sfpi1 expression was not STAT6 dependent, as determined by comparison of wild-type and Stat6 −/− T H 9 cell cultures (data not shown). As both iT reg and T H 17 cell cultures have been suggested to produce 26, 28) , we also directly compared cells cultured under those conditions with T H 9 cell cultures. By intracellular staining and enzyme-linked immunosorbent assay (ELISA), we observed low or undetectable IL-9 production by iT reg cell cultures (Fig. 1e and data not shown) . In comparing T H 9 and T H 17 cell cultures, we observed little IL-9 production in T H 17 cell culture assays by intracellular staining or ELISA, although there was a small amount of IL-17 production by T H 9 cell cultures (Fig. 1f,g ). Because we detected IL-9 in T H 2 cell cultures, we separated T H 2 populations into IL-4 hi and IL-4 lo populations 8 and observed that Il9 expression segregated with Sfpi1 expression in the IL-4 lo cells and segregated away from Il4 expression (Fig. 1h) .
To define if PU.1 was a determining factor in promoting IL-9 secretion, we ectopically expressed PU.1 with a bicistronic retrovirus in T H 2, T H 9 and iT reg cell cultures and examined cytokine secretion and gene expression in sorted cells positive for enhanced green fluorescent protein (eGFP). Higher PU.1 expression in T H 2 or T H 9 cell cultures further induced IL-9 production, as assessed by both ELISA and intracellular cytokine staining and measurement of Il9 mRNA in these cultures (Fig. 2) . Ectopic PU.1 expression in T H 2 cells, as described before 8 , resulted in lower expression of T H 2 cytokines (Fig. 2c) . Although ectopic PU.1 expression resulted in lower expression of the gene encoding the transcription factor Foxp3 in iT reg cell cultures (Supplementary Fig. 1b) , it did not induce Il9 expression in these cells (data not shown). The generation of iT reg cells by PU.1-deficient cells was normal, and the ability of IL-4 to repress Foxp3 was not substantially impaired in the absence of PU.1 expression (Supplementary Fig. 1c,d) . Moreover, there was not a greater number of CD4 + Foxp3 + cells in a variety of Sfpi1 fl/fl Lck-Cre lymphoid organs than in those of wild-type mice ( Supplementary Fig. 1e,f) , which suggested that PU.1 deficiency does not affect Foxp3 expression. These results suggest that PU.1 promotes the IL-9-secreting T cell phenotype but that additional IL-4-induced signals are required for the generation of T H 9 cells. 
IL-9 and IL-10 are not coordinately regulated
Published reports of IL-9-secreting T cells have suggested that they also express IL- 10 (refs. 24,29) . In contrast, another report has demonstrated that expression of IL-9 and IL-10 in T H 2 cells is reciprocally regulated 9 . To further examine this issue, we differentiated T H 2 and T H 9 cells from cultures of naive CD4 + T cells with IL-4 or a combination of IL-4 and TGF-β1, respectively. Although we detected IL-10 in T H 9 cells, production was lower than that in T H 2 cell cultures ( Fig. 3a,b) . Moreover, additional treatment of T H 9 cell cultures had a reciprocal effect on the production of IL-9 and IL-10. We observed more IL-9 production by T H 9 cell cultures when they were differentiated in the presence of antibody to IL-10 (anti-IL-10), and this was concomitant with less IL-10 production (Fig. 3c) . The addition of IL-9 to T H 2 cell cultures did not affect IL-10 production (data not shown). The addition of TGF-β1 to differentiated T H 9 cell cultures, during anti-CD3 restimulation, resulted in more IL-9 production but less IL-10 production (Fig. 3d) . Although PU.1 deficiency resulted in less IL-9 production ( Fig. 1) , it did not affect IL-10 production by T H 9 cell cultures (Fig. 3e ). Thus, although T H 9 cell cultures may produce IL-10, IL-9 and IL-10 are not coordinately regulated.
PU.1 required for chromatin modifications of Il9
As helper T cell specification is associated with specific chromatin structure, we examined by chromatin-immunoprecipitation (ChIP) assay chromatin modifications at the Il9 locus in naive T cells and in naive T cells cultured for 5 d under T H 1, T H 2, T H 9 or T H 17 conditions. Total acetylation of both histone H3 and H4 and acetylation of histone 3 Lys9 (H3K9) and H3K18 at two Il9 conserved noncoding sequences (CNSs; Fig. 4a) were highest in T H 9 cell cultures compared with that of all other subsets (Fig. 4b) , although all subsets demonstrated more acetylation than did naive cells. T H 9 cells also had the least trimethylated H3K27, a modification associated with repressed genes (Fig. 4b) .
Cultures of iT reg cells had histone acetylation similar to that of T H 9 cells (Fig. 4c) , in agreement with data on the Il9 locus derived from genome-wide studies 30 . However, the Il9 locus had more trimethylated H3K27 in iT reg cell cultures than in T H 9 cell cultures ( Fig. 4c) . Thus, active Il9 expression was associated with a combination of high H3 acetylation and low H3K27 methylation. To determine whether PU.1 was required for the establishment of these chromatin modifications, we differentiated wild-type and PU.1-deficient naive T cells under T H 9 conditions and analyzed chromatin modifications. We observed that H3 acetylation, the modification that showed the greatest difference between T H 9 and other helper T cell cultures, was lower in the absence of PU.1 at both CNS sites ( Fig. 4d ) and that this effect was specific for T H 9 cell cultures, as PU.1 deficiency did not affect H3 acetylation of Il9 in T H 2 or T H 17 cells (Supplementary Fig. 2 ). Moreover, the presence of the Cre transgene did not result in less Il9 H3 acetylation ( Supplementary Fig. 2 ). In contrast, H4 acetylation or H3K27 methylation was not affected by the absence of PU.1 (Fig. 4e) . These results suggest that PU.1 is required for 'programming' of the Il9 locus but has a restricted role in the histone modifications that are affected.
To determine if PU.1 was acting directly on Il9, we examined CNS1 for consensus PU.1-binding sites (5′-GGAA-3′ core sequence). We found two potential sites in sequences conserved among human, mouse and dog Il9 promoters (Fig. 4f) . Using DNA-affinity-precipitation assay of extracts of T H 2 or T H 9 cells, followed by immunoblot analysis, we observed binding of PU.1 to both sites, with stronger binding to site 2, and binding was decreased by incubation with a nonbiotinylated A r t i c l e s competitor oligonucleotide (Fig. 4f and data not shown). We observed more PU.1 binding with extracts of T H 9 cells, parallel to higher PU.1 protein expression in extracts of T H 9 cells (Fig. 4f) . We then assessed by ChIP assay whether PU.1 bound to the Il9 promoter. After differentiation of T H 1, T H 2 and T H 9 cells, PU.1 ChIP assays detected binding of PU.1 to the Il9 promoter in T H 9 cells, with no detectable binding in T H 1 or T H 2 cells (Fig. 4g) . Thus, PU.1 binds to sites in the Il9 promoter specifically in T H 9 cells.
PU.1 is required for IL-9 production in human T cells
The ability of conditions that promote the development of mouse T H 9 cells to promote a human T H 9 cell phenotype has not been tested.
To assess the derivation of human T H 9 cells, we cultured naive CD4 + T cells purified from peripheral blood under T H 2 or T H 9 conditions. As with mouse cells, the addition of TGF-β1 to T H 2 cultures resulted in less T H 2 cytokine production and more production of IL-9 ( Fig. 5a-c) . Human T H 9 cell cultures also expressed more SPI1 than did T H 2 cell cultures (Fig. 5a) . We then determined if PU.1 was required for IL-9 expression in human T H 9 cells by transfecting differentiated human T H 9 cell cultures with control or SPI1-specific small interfering RNA (siRNA) before restimulating the cells. Inhibiting SPI1 expression resulted in less IL-9 production (Fig. 5d,e) . These results suggested that the ability of PU.1 to promote the development of IL-9-secreting T cells is conserved in human and mouse cells.
T H 9 cells and allergic inflammation
The role of IL-9 in allergic inflammation is still unclear. To begin to explore this area further, we examined IL-9 production by anti-CD3-stimulated peripheral blood mononuclear cells (PBMCs) from atopic children (positive for at least one allergen-specific immunoglobulin E (IgE) of ten examined) and nonatopic children (no allergen-specific IgE) with ages ranging from 18 months to 30 months. This cohort has been described in greater detail 31 . Notably, whereas these children show signs of developing atopy, they have not had episodes of wheezing and are not considered asthmatic. IL-9 production was significantly greater in atopic patients than in nonatopic patients (Fig. 5f) .
To further examine the role of PU.1-dependent T cell function in allergic inflammation, we subjected wild-type and Sfpi1 fl/fl Lck-Cre mice to a standard protocol for the development of ovalbumin (OVA)-induced allergic airway inflammation. We sensitized mice with OVA in aluminum hydroxide (alum) and challenged them intranasally with OVA in PBS. We first tested the generation of helper T cell responses in the periphery by stimulating splenic cells with OVA or anti-CD3. Consistent with published in vitro analyses 7, 8 , there was no impairment of T H 2 cytokine responses in Sfpi1 fl/fl Lck-Cre mice compared with those of wild-type mice (Fig. 6a ). The production of T H 17 cytokines was also unimpaired by the absence of PU.1 (Supplementary Fig. 3 ). The generation of antigen-specific IgE and IgG1 was not significantly different in wildtype versus Sfpi1 fl/fl Lck-Cre mice (P > 0.15; data not shown).
In contrast to the normal development of peripheral responses, inflammation in the lung was lower in mice with PU.1-deficient T cells than in wild-type mice (Fig. 6b) . Sfpi1 fl/fl Lck-Cre mice also demonstrated significantly less airway hyper-responsiveness in response to methacholine challenge than did wild-type mice (Fig. 6c) . Analysis of the cellular composition of bronchoalveolar lavage (BAL) fluid demonstrated greater infiltration in challenged wild-type and Sfpi1 fl/fl Lck-Cre mice than in unchallenged mice, but total cell numbers and the cell numbers of specific cell populations, including eosinophils, were lower in Sfpi1 fl/fl Lck-Cre mice than in wild-type mice (Fig. 6d) . To confirm that Lck-Cre-mediated deletion of the Sfpi1 allele did not affect the PU.1-dependent development of dendritic cells important for the development of inflammation, we examined 
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CD11b + and CD103 + subpopulations of CD11c + major histocompatibility complex class II-positive cells in BAL fluid and lung-cell suspensions of nonsensitized and unchallenged mice and observed no significant differences between wild-type and Sfpi1 fl/fl Lck-Cre mice (P > 0.2; data not shown). There were smaller amounts of IL-9 and T H 2 cytokines present in BAL fluid (Fig. 6e) . In contrast, the amount of interferon-γ and IL-17 present in the BAL fluid was not affected (data not shown).
To demonstrate that blocking IL-9 could result in a similar phenotype, we used the OVA-induced allergic airway inflammation model for wild-type mice treated with control or anti-IL-9 administered intravenously at the first, third and fifth challenges. We observed less inflammation and lower numbers of allergic inflammatory cells in mice treated with anti-IL-9 than in mice treated with control antibody (Fig. 6f,g ). This result confirmed a role for IL-9 in this model established before with a similar protocol and BALB/c mice 18 .
To determine if Il9 expression was lower in T cells from sensitized Sfpi1 fl/fl Lck-Cre mice than in those from wild-type mice, we used quantitative PCR to assess mRNA abundance in antigen-stimulated splenocyte cultures. We observed less Il9 mRNA in Sfpi1 fl/fl Lck-Cre cultures (Fig. 7a) . It was possible that PU.1 was regulating other genes A r t i c l e s associated with a T H 9 phenotype. PU.1 expression segregates with expression of the gene encoding the chemokine CCL22 in IL-4 lo cells, and ectopic PU.1 expression results in more CCL22 production 8 . Consistent with those observations, we observed that chemokines associated with allergic inflammation, CCL17 and CCL22, were produced less abundantly by antigen-stimulated Sfpi1 fl/fl Lck-Cre cultures than by wild-type cultures (Fig. 7a) . Conversely, ectopic expression of PU.1 induced the expression of both chemokines in T H 9 cell cultures (Fig. 7b) . To determine if the deficiency in chemokine production by T cells was reflected in the allergic inflammation model, we analyzed whole-lung homogenates for Ccl17 mRNA and Ccl22 mRNA. Although mRNA for both chemokines was present in tissue from sensitized and challenged mice, both were less abundant in Sfpi1 fl/fl Lck-Cre lung tissue than in wild-type lung tissue (Fig. 7c) . These results suggest that PU.1 in T cells regulates allergic inflammation by inducing the expression of IL-9 and proallergic chemokines.
DISCUSSION
The defined phenotypes of effector helper T cell subsets, once classified simply as T H 1 and T H 2, have been expanded to include T H 17 cells, follicular helper T cells and iT reg cells. An IL-9-secreting T cell, the 'T H 9 cell' , has been identified as arising after treatment with a cytokine combination of TGF-β1 and IL- 4 (refs. 24,29) . Distinguishing these subsets has become more difficult as the plasticity of the phenotypes has become apparent 32 . However, each lineage expresses transcription factors that are lineage-determining factors or that promote particular aspects of the lineage genetic program. The T H 9 lineage, if it is indeed a separate lineage, is related to the T H 2 lineage by the developmental requirement for IL-4 and the downstream transcription factors STAT6 and GATA- 3 (refs. 24,29) . In this report, we have identified PU.1 as a transcription factor that induces the T H 9 phenotype by promoting the expression of IL-9 and proallergic chemokines.
In published analyses of PU.1 in T H 2 cells, PU.1 expression has been found to segregate with a subpopulation of T H 2 cells with low expression of IL-4 and other T H 2 cytokines 8 . That observation corresponds with the ability of ectopically expressed PU.1 to inhibit the production of T H 2 cytokines and the ability of decreasing PU.1 expression, either by siRNA or gene deletion, to increase T H 2 cytokine production 7, 8 . This function is at least in part due to interference with factors that promote the T H 2 phenotype, including GATA-3 and IRF4 (refs. 8,9) . The data presented in our report here suggest that the IL-4 lo T H 2 subset characterized before might contain some T H 9 cells. Given the apparent plasticity of T H 2 cells in acquiring a T H 9 phenotype 24 , these two cell types might exist in a continuum in which increasing PU.1 expression would lead to decreasing T H 2 cytokines and increasing characteristics of the T H 9 phenotype, with intermediate phenotypes being possible.
Our data have indicated that PU.1 can bind the Il9 promoter directly in T H 9 cells and that conserved PU.1-binding sites exist in CNS1. Although ectopic expression of PU.1 enhanced the T H 9 characteristics of cells and converted T H 2 cells to a T H 9 phenotype, it had more modest effects on the induction of Il9 in iT reg , T H 1 or T H 17 cell cultures (data not shown). These results might suggest that whereas PU.1 promotes the T H 9 phenotype, it may be most active in cells in which additional factors are present to mediate these effects. This scenario is not uncommon in the helper T cell differentiation paradigm. As described above, many factors contribute to the T H 2 phenotype and many factors, including T-bet, STAT4, Hlx and Runx3, contribute to the T H 1 genetic program [33] [34] [35] . One possible context requirement might be lower expression of IRF4, which we have demonstrated repressed Il9 in T H 2 cultures and is further required for the development of T H 17 cells 9, 36 . Preliminary observations suggest that Irf4 expression is lower in T H 9 cells than in T H 2 cells (data not shown). The chromatin modifications present at the Il9 locus in each of these cell types may also reflect the ability of PU.1 to induce Il9 mRNA. The activity of the Il9 locus correlated with the combination of more histone acetylation and less H3K27 methylation. However, in iT reg cell cultures that had a similar extent of histone acetylation but abundant H3K27 methylation at the Il9 locus, we did not detect induction of Il9 by PU.1. The ability of PU.1 to induce IL-9 in T H 2 but not iT reg cell cultures suggests that additional IL-4-induced factors exist that are required for acquisition of the IL-9-secreting phenotype. Although GATA-3 is required for T H 9 development 29 , it seems an unlikely candidate, as T H 9 cultures have only low GATA-3 expression 24, 29 and PU.1 antagonizes GATA-3 activity in helper T cells 7, 8 . IRF4 also seems unlikely, as it represses Il9 expression in T H 2 cells and PU.1 antagonizes its function 9 . It will be useful to determine if other transcription factors, in the presence of PU.1, promote Il9 expression.
The relatedness of the T H 2 and T H 9 phenotypes and the requirement for STAT6 and GATA-3 in the development of both subsets 24, 29 raise some questions about phenotypes that have been described for mice deficient in either STAT6 or GATA-3, specifically whether phenotypes in allergic inflammation and parasite immunity are a result of defects in the development of one or both subsets. A published report has demonstrated that mice with defective TGF-β1 signaling have less parasite clearance that correlates with less IL-9 (ref. 24) . Similarly, in this report we have shown defects in the development of allergic inflammation in mice with fewer IL-9-secreting T cells but normal development of T H 2 immunity. These findings suggest that T H 9 cells might be required for what has classically been called T H 2 immunity, and there are ample data that support the idea of a role for IL-9 in allergic disease. Transgenic models have demonstrated that IL-9 can promote the development of allergic inflammation 12, 13 and that blockade of IL-9 inhibits this development 18 . Moreover, more IL-9 is found in lungs of patients with asthma 20, 21 , and we found that T cells from patients with atopic disease secreted more IL-9 than did T cells from nonatopic patients. Notably, this observation does not diminish the role of T H 2 cytokines in the development of allergic inflammation and instead suggests that these two helper T cell subsets work in concert to initiate allergic inflammation. IL-9 can promote the development of T H 17 cells and is also reported to be produced by T H 17 cells 25, 26 . Thus, the lower allergic inflammation in mice with PU.1-deficient T cells might be interpreted to result from the diminished generation of T H 17 cells, which are required for the development of inflammation in this model 37 . However, we did not see a lower ability of PU.1-deficient T cells to acquire the T H 17 phenotype in vitro, and ectopic expression of PU.1 did not induce IL-17 production (data not shown). Moreover, IL-17 production by mice that were sensitized and challenged was higher in OVA-stimulated splenocyte cultures from Sfpi1 fl/fl Lck-Cre mice than in those from wild-type mice. This finding suggests that PU.1 is not required for T H 17 development. TGF-β1 seems to be an important factor in promoting IL-9 production from cells cultured with various cytokines 26, 27 . It is possible that whereas TGF-β1 promotes IL-9 production, the addition of IL-4 alters the phenotype such that T H 17 cytokine production is lower and resulting cells mainly produce IL-9 alone. In our experiments, T H 9 cell cultures produced IL-9, which was barely detectable in T H 17 cell cultures, and T H 9 cell cultures produced less IL-17 than did T H 17 cells. Thus, whereas there may be overlap in the cytokine signatures of these subsets, highly polarized cells might still have distinct functional properties.
The precise contribution of PU.1-expressing T cells to allergic inflammation remains undefined and is probably a combination of altered expression of IL-9 and chemokines. Our data have confirmed that blocking IL-9 with antibodies resulted in less allergic inflammation in the OVA-induced model. As the previously published report noted above used BALB/c mice 18 and our study used C57BL/6 mice, our data have demonstrated that the effects of blocking IL-9 are not strain specific. The chemokines CCL17 and CCL22 and their receptor, CCR4, are each important in the development of allergic inflammation [38] [39] [40] . One possibility is that PU.1-dependent chemokine production by T cells is responsible for the diminished allergic inflammation of Sfpi1 fl/fl Lck-Cre mice. This possibility represents an addition to the present paradigm in which T cells in the lung secrete cytokines, such as IL-13, that promote chemokine production by resident lung cells, including epithelial cells, smooth muscle cells and fibroblasts 41 . Our results suggest that chemokine production by T cells also contributes to the overall extent of inflammation. PU.1-dependent production of IL-9 or the expression of other PU.1-dependent genes may also contribute to inflammation in this model, and the phenotype we observed may indeed be caused by several different factors. As the PU.1-dependent genetic program in T cells becomes better defined, the role of these factors can be assessed more directly.
The description of an IL-9-secreting T cell population has added further complexity to the understanding of effector helper T cell phenotypes. One factor that prevented this population from initially being called a 'lineage' was the absence of an identified transcription factor that confers lineage-specific expression. Our work has identified PU.1 as a factor that promotes the T H 9 phenotype by both repressing T H 2 cytokine production and increasing IL-9 production. PU.1 is probably not the only factor that promotes this lineage but will be an important component of continuing investigations into helper T cell heterogeneity.
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Supported by the National Institutes of Health (R01 AI57459 and U19 AI070448 to M.H.K., R01 CA118118 to M.J.R.; R01 HL080071 to R.S.T.; and T32 AI060519 to G.L.S.). with an RNeasy kit (Qiagen) was used for synthesis of cDNA for subsequent analysis. Peripheral immune responses in sensitized and challenged wild-type or Sfpi1 fl/fl Lck-Cre mice were assessed by culture of splenocytes for 72 h with anti-CD3 (4 μg/ml) or OVA (100 μg/ml) before cytokines in cell-free supernatants were assessed by ELISA. Paraffin-embedded sections were stained with hematoxylin and eosin for evaluation of the infiltration of inflammatory cells by light microscopy.
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Airway hyper-reactivity. Airway hyper-reactivity to methacholine challenge was determined 24 h after the final intranasal challenge as described above. Noninvasive unrestrained whole-body plethysmography (Buxco Research Systems) was used to record airway responsiveness with the dimensionless parameter 'enhanced pause' for estimation of total pulmonary resistance, an indicator of bronchoconstriction. Mice were placed in whole-body plethysmographs and baseline measurements were recorded. Saline was administered by nebulization for 2 min, followed by increasing doses of methacholine, and the enhanced-pause parameter was recorded over 5 min.
